Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Snyder, R. D.
Right arrow Articles by Diehl, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Snyder, R. D.
Right arrow Articles by Diehl, M. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Mutagenesis, Vol. 15, No. 3, 203-205, May 2000
© 2000 UK Environmental Mutagen Society/Oxford University Press

The bleomycin amplification assay in V79 cells predicts frameshift mutagenicity of intercalative agents

Ronald D. Snyder1 and Marilyn S. Diehl

Abbott Laboratories, D-468, AP13A, 100 Abbott Park Road, Abbott Park, IL 60064, USA

We have recently reported on the use of a cell-based bleomycin amplification assay for the detection of DNA intercalating agents. In order to further validate this assay, two series of proprietary compounds were evaluated for frameshift mutagenesis in the Ames bacterial reversion system and for bleomycin amplification in the Chinese hamster V79 micronucleus system. It is shown that 10 of 11 frameshift-positive compounds were bleomycin amplifiers. These studies indicate that positive frameshift mutagenicity findings are consistent with expectations from the results of the bleomycin amplification assay, providing additional validation of the amplification assay for the detection of DNA intercalating agents. The studies also demonstrate that intercalation is necessary but not sufficient for frameshift mutagenesis since bleomycin amplifiers lacking frameshift mutagenic activity were also identified.

1 To whom correspondence should be addressed at: DuPont Pharmaceuticals, Stine-Haskell Research Center, PO Box 30, H1/1710, Newark, DE 19714-0030, USA. Tel: +1 302 451 4503; Fax: +1 302 451 4827; Email: ronald.d.snyder{at}dupontpharma.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 MutagenesisHome page
G. R. Hoffmann, M. V. Ronan, K. E. Sylvia, and J. P. Tartaglione
Enhancement of the recombinagenic and mutagenic activities of bleomycin in yeast by intercalation of acridine compounds into DNA
Mutagenesis, July 1, 2009; 24(4): 317 - 329.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
J. C. S. Kleinjans, M. H. M. van Herwijnen, J. M. S. van Maanen, L. M. Maas, T. M. C. M. de Kok, H. J. J. Moonen, and J. J. Briede
In vitro investigations into the interaction of {beta}-carotene with DNA: evidence for the role of carbon-centered free radicals
Carcinogenesis, July 1, 2004; 25(7): 1249 - 1256.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.